- Home
- PRCT vs QURE Comparison
PRCT vs QURE Comparison
Compare PRCT & QURE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PRCT | QURE |
|---|---|---|
| Founded | 2009 | 1998 |
| Country | United States | Netherlands |
| Employees | N/A | 248 |
| Industry | Medical Specialities | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.1B |
| IPO Year | 2021 | 2013 |
Fundamental Metrics
Financial Performance| Metric | PRCT | QURE |
|---|---|---|
| Price | $21.41 | $47.01 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 11 | 14 |
| Target Price | $35.44 | ★ $45.00 |
| AVG Volume (30 Days) | 1.4M | ★ 1.9M |
| Earning Date | 04-29-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 1.71 | ★ 29.67 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $308,054,000.00 | $13,107,000.00 |
| Revenue This Year | $31.34 | $126.12 |
| Revenue Next Year | $24.52 | $200.43 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 37.22 | N/A |
| 52 Week Low | $19.35 | $8.73 |
| 52 Week High | $62.17 | $71.50 |
Technical Indicators
Market Signals| Indicator | PRCT | QURE |
|---|---|---|
| Relative Strength Index (RSI) | 33.45 | 79.94 |
| Support Level | $19.35 | $21.63 |
| Resistance Level | $29.27 | $60.70 |
| Average True Range (ATR) | 1.72 | 2.40 |
| MACD | -0.85 | 1.74 |
| Stochastic Oscillator | 8.21 | 85.78 |
Price Performance
Historical ComparisonAbout PRCT PROCEPT BioRobotics Corporation
PROCEPT BioRobotics Corp is a surgical robotics company focused on advancing patient care by developing transformative solutions in urology. The company develops, manufactures, and sells the AquaBeam Robotic System and HYDROS Robotic System, image-guided, surgical robotic systems for use in minimally invasive urologic surgery, with an initial focus on treating benign prostatic hyperplasia, or BPH. Geographically, the company generates a majority of its revenue from the United States and also has a presence in markets outside the U.S.
About QURE uniQure N.V.
uniQure NV is a gene therapy company. It develops treatments and platforms for patients suffering from genetic and other devastating diseases. Its products and services are focused on hemophilia, Huntington's disease, and cardiovascular diseases. The company is focused on the development of the pipeline of gene therapies with the collaboration of Bristol Myers Squibb for cardiovascular diseases. Its program and pipeline involves: Huntington's Disease, Temporal Lobe Epilepsy (TLE), Fabry Disease, ALS (SOD1), Hemophilia B, Clinical Trials, and Research Programs.